Myriad myPlan™ Lung Cancer measures
expression levels of critical cell cycle genes. Combined with pathologic
tumor stage, the result is correlated with the 5-year risk of lung cancer
death—guiding physicians in making
chemotherapy decisions for early-stage patients.
Myriad myPath™ Melanoma is a unique molecular test created specifically for difficult-to-diagnose melanoma cases. By analyzing 23 genes, the test provides valuable additive molecular information unavailable from any other method for a more informed diagnosis.
Prolaris® measures the expression level of genes involved with tumor proliferation, providing physicians with unique additional information about a patient’s prostate cancer prognosis and may be used with other clinical factors - providing valuable insight into treatment planning.
Myriad ResultsNow™ electronically delivers Myriad test results. Easily view your patient’s test results from anywhere there is an internet connection. View from your office, home, on any hand-held device.
Medicare pays for genetic testing when specific criteria are met. Healthcare providers should consult Medicare's web site to determine if the patient meets Medicare's testing criteria for genetic testing. Healthcare providers can also obtain assistance in interpreting the criteria from Myriad's Medical Services by calling Myriad at 800-469-7423, option 2.
For all Medicare patients, a copy of the signed informed consent is required before testing will begin. For patients who do not meet Medicare criteria, an Advanced Beneficiary Notice of Non-coverage (ABN for Hereditary Cancer) (ABN for Personalized Medicine) is also required before testing will begin.
Because Medicare will likely not cover test costs for patients who do not meet Medicare criteria, test costs will be billed to the patient. A summary of instructions and documentation requirements for Medicare patients is included on page one of the ABN.
Annual Notice to Providers
Medicare, Medicaid, or other federally funded programs will pay only for tests that meet their coverage criteria and are reasonable and necessary to treat or diagnose a patient. Medicare generally does not cover routine screening tests even if the physician or individuals authorized by law to order tests considers the tests appropriate for the patient.
Laboratories are required to provide annual notice of these restrictions to physicians and other individuals ordering laboratory services. Here you will find an electronic copy of those notices.
BRACAnalysis, COLARIS, COLARIS AP, MELARIS, Myriad myPath, myPlan, myRisk, TheraGuide, PREZEON, PANEXIA, and
Prolaris are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions